117.88MMarket Cap-1.47P/E (TTM)
0.993High0.891Low403.33KVolume0.950Open0.943Pre Close368.41KTurnover0.50%Turnover RatioLossP/E (Static)129.54MShares4.44052wk High-0.12P/B73.20MFloat Cap0.86552wk Low--Dividend TTM80.44MShs Float14.190Historical High--Div YieldTTM10.85%Amplitude0.865Historical Low0.913Avg Price1Lot Size
ProKidney Stock Forum
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
No comment yet